Abstracts tagged "Biologics"

Abstract Number: 1249 • 2017 ACR/ARHP Annual Meeting
What Factors Predict Good Patient Experiences of Switching from Reference Etanercept (EnbrelTM) to an Etanercept Biosimilar (BenepaliTM) in a South West London General Hospital?
Laura Attipoe, Samir Patel, Robin Birt, Jennifer Crooks and Antigoni Grigoriou, Rheumatology, Kingston Hospital, Kingston, London, England, Kingston, United Kingdom
Background/Purpose: The introduction of biological (BG) drugs in the last 20 years has revolutionised the treatment of patients with inflammatory arthritis (IA). The development of…
Abstract Number: 1553 • 2017 ACR/ARHP Annual Meeting
Discontinuation of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Désirée van der Heijde², Chitra Karki³, Mei Liu³, Yujin Park⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Leiden University Medical Center, Leiden, Netherlands, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: There is a need to better characterize patients with ankylosing spondylitis (AS) who discontinue vs continue TNF inhibitor (TNFi) therapies in real-world clinical settings.…
Abstract Number: 2489 • 2017 ACR/ARHP Annual Meeting
Efficacy and Survival of Biologic DMARD Therapies As Monotherapy: Real World Data
Jose A Gómez-Puerta^1,2, Natalia Duque Zapata¹, Luis Alonso Gonzalez^1,3, Carmen Cerón¹, Monica Vásquez¹ and Oscar Jair Felipe Diaz^1,4, ¹Medicarte IPS, Medellín, Colombia, ²Grupo de Reumatología, Universidad de Antioquia, Medellín, Colombia, ³Grupo de Reumatología, Universidad de Antioquia, Medellin, Colombia, ⁴Clinica Las Vegas, Medellín, Colombia
Background/Purpose: According different international registries, around one third of patients under biologic DMARD (bDMARD) with rheumatoid arthritis (RA) are receiving bDMARD as monotherapy (1-4). In…
Abstract Number: 2969 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: 52-Week Results from a Phase 3 Study
Mark C. Genovese¹, Bernard Combe², Joel Kremer³, David Adams⁴, Chin Lee⁴, Lisa Kerr⁴ and Peter Nash⁵, ¹Stanford University Medical Center, Palo Alto, CA, ²Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ³St. Peter's Hospital, Albany, NY, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of Queensland, Brisbane, Australia
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A. In patients with active psoriatic arthritis (PsA) who had an inadequate response…
Abstract Number: 141 • 2017 ACR/ARHP Annual Meeting
Refractory Disease in Rheumatoid Arthritis: Results from the British Society of Rheumatology Biologics Register for Rheumatoid Arthritis
Lianne Kearsley-Fleet¹, Diederik De Cock¹, Kath Watson¹, Maya H. Buch², John D Isaacs³ and Kimme L. Hyrich^1,4, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, ⁴National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Biologic therapy has revolutionised treatment pathways and improved outcomes for patients with Rheumatoid Arthritis (RA) who do not tolerate or respond to conventional synthetic…
Abstract Number: 618 • 2017 ACR/ARHP Annual Meeting
Secukinumab Sustains Individual Clinical Responses over Time in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 3 Trial
Paul Emery¹, Iain B. McInnes², Philip J Mease³, Michael Schiff⁴, Luminita Pricop⁵, Steven Shen⁵, Zailong Wang⁵ and Corine Gaillez⁶, ¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Colorado, Denver, CO, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Achieving, sustaining, and improving clinical responses to biologics in PsA are important parts of EULAR and GRAPPA recommendations aimed to optimize treatment goals.1,2 Here…
Abstract Number: 1423 • 2017 ACR/ARHP Annual Meeting
Patterns of Prednisone Use in US Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine Clinical Practice
Dimitrios A. Pappas¹, Carol J. Etzel², Jennie Best³, Steve Zlotnick³, Taylor Blachley², Gioia Persuitte² and Joel Kremer⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: There are limited data regarding the impact of tocilizumab (TCZ) treatment on prednisone use in patients with rheumatoid arthritis (RA). The objective of this…
Abstract Number: 1554 • 2017 ACR/ARHP Annual Meeting
Discontinuation and Switching Patterns By TNFi Line of Therapy in Patients with Psoriatic Arthritis—Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Chitra Karki², Mei Liu², YouFu Li³, Peter Hur⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³University of Massachusetts Medical School, Worcester, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Few real-world studies have characterized the use of first- vs second-line tumor necrosis factor inhibitors (TNFis) in US patients with psoriatic arthritis (PsA). This…
Abstract Number: 2492 • 2017 ACR/ARHP Annual Meeting
The Long-Term Safety and Durability of Response of Chs-0214, a Proposed Biosimilar to Etanercept: An Open-Label Safety Extension Study
Ingrid Louw¹, Alan J. Kivitz², Tsutomu Takeuchi³, Yoshiya Tanaka⁴, Satoshi Nakashima⁵, Jennifer Hodge⁶, Hong Tang⁶, Paula O'Connor⁶ and Barbara Finck⁶, ¹Panorama Medical Centre, Cape Town, South Africa, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ³Keio University School of Medicine, Tokyo, Japan, ⁴School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Daiichi Sankyo, Tokyo, Japan, ⁶Coherus BioSciences, Inc., Redwood City, CA
Background/Purpose: CHS-0214 is a proposed biosimilar to etanercept for the treatment of rheumatoid arthritis and other auto-immune diseases. Two randomized, double-blind studies demonstrated equivalence of…
Abstract Number: 202 • 2017 ACR/ARHP Annual Meeting
Analysis of Provider-to-Provider Variability in the Use of Biologics: Data from the Rheumatology Informatics System for Effectiveness Registry
Douglas White¹, Michael Evans², Gabriela Schmajuk³, Rachel Myslinski⁴, Salahuddin Kazi⁵ and Jinoos Yazdany⁶, ¹Gundersen Health System, Onalaska, WI, ²University of California San Francisco, San Francisco, CA, ³San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, ⁴Practice, Advocacy, & Quality, American College of Rheumatology, Atlanta, GA, ⁵University of Texas Southwestern, Dallas, TX, ⁶Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Variations in biologic prescribing habits by rheumatology providers may account in part for variability in direct cost of care for patients with rheumatoid arthritis…
Abstract Number: 621 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvement in Major and Moderate Response of Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study
Josef S. Smolen¹, Philip J Mease², Christopher T. Ritchlin³, Tore K Kvien⁴, Luminita Pricop⁵, Todd Fox⁶, Lawrence Rasouliyan⁷, Steffen Jugl⁶ and Corine Gaillez⁶, ¹Medical University of Vienna, Vienna, Austria, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷RTI Health Solutions, Barcelona, Spain
Background/Purpose: DAPSA score is a validated tool to measure disease activity states and response criteria, focusing on peripheral joint involvement in patients (pts) with PsA.1…
Abstract Number: 1433 • 2017 ACR/ARHP Annual Meeting
Tailoring Second-Line Biologic Therapy in Rheumatoid Arthritis: New Findings on the Usefulness of Antibody Status to Optimise Drug Selection
Muhammad Shipa¹, Maria Di Cicco², Emese Balogh², Aneela Mian³, Dev Mukerjee⁴ and Euthalia Roussou², ¹Rheumatology and General internal Medicine, North Middlesex University Hospital NHS trust, London, United Kingdom, ²Barking Havering and Redbridge University hospitals NHS Trust, London, United Kingdom, ³Rheumatology, King's College London, London, United Kingdom, ⁴Rheumatology, North Middlesex University Trust, London, United Kingdom
Background/Purpose: Treatment of rheumatoid arthritis (RA) has been revolutionized by the introduction of Tumour Necrosis Factor alpha inhibitors (TNFi). However a significant proportion of patients…
Abstract Number: 1785 • 2017 ACR/ARHP Annual Meeting
Serious or Opportunistic Infections in Infants Born to Pregnant Women with Rheumatoid Arthritis and Treated with a Biologic Medication
Christina D Chambers¹, Diana L Johnson², Yunjun Luo³, Ronghui Xu⁴ and Kenneth L Jones³, ¹Pediatrics and Family Medicine and Public Health, University of California San Diego, La Jolla, CA, ²Department of Pediatrics, University of California, San Diego, La Jolla, CA, ³Pediatrics, University of California San Diego, La Jolla, CA, ⁴Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA
Background/Purpose: Use of biologic therapies for rheumatoid arthritis (RA) in pregnancy is common. There is theoretical concern that these medications could interfere with postnatal…
Abstract Number: 2520 • 2017 ACR/ARHP Annual Meeting
Incidence of Extra-Articular Manifestations in Psa and As Patients Treated with Golimumab in Canadian Real-World
Michelle Teo¹, Derek Haaland², John Kelsall³, Isabelle Fortin⁴, Pauline Boulos⁵, Raman Rai⁶, Sanjay Dixit⁷, B Haraoui⁸, Dalton Sholter⁹, Eliofotisti Psaradellis¹⁰, Emmanouil Rampakakis¹⁰, Brendan Osborne¹¹, Francois Nantel¹¹ and Allen J Lehman¹², ¹Balfour Medical Clinic, Penticton, BC, Canada, ²Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ³Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁴Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, ⁵Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Private Practice, Hamilton, ON, Canada, ⁷Rheumatology, McMaster University Hamilton, Burlington, ON, Canada, ⁸Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁹Rheumatology Associates, Edmonton, AB, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada
Background/Purpose: Spondyloarthropathies (SpA) encompass a heterogeneous group of chronic inflammatory diseases affecting axial and peripheral joints. Besides articular symptoms, patients also experience extra-articular manifestations (EAMs)…
Abstract Number: 311 • 2017 ACR/ARHP Annual Meeting
Total Ankle Arthroplasty for Rheumatoid Arthritis Cases in This Biologics Era: Mid to Long-Term Follow-up
Makoto Hirao¹, Jun Hashimoto², Hideki Tsuboi³, Kosuke Ebina⁴ and Hideki Yoshikawa⁵, ¹Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ²Rheumatology/Orthopaedics, Osaka-Minami Medical Ctr, Kawachinagano, Japan, ³Orthopaedics/Rheumatology, Osaka Rosai Hospital, Sakai, Japan, ⁴Orthopaedics, Osaka University Graduate School of Medicine, Suita, Japan, ⁵Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: Outcomes after total ankle arthroplasty (TAA) combined with additive techniques (augmentation of bone strength, control of soft tissue balance, adjustment of the loading axis)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].